Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bank of America Corp DE lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 747,934 shares of the company's stock after purchasing an additional 41,390 shares during the period. Bank of America Corp DE owned about 0.87% of IDEAYA Biosciences worth $19,222,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. R Squared Ltd bought a new position in IDEAYA Biosciences in the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after acquiring an additional 853 shares in the last quarter. KBC Group NV lifted its stake in shares of IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after purchasing an additional 1,923 shares during the last quarter. Cibc World Markets Corp bought a new stake in IDEAYA Biosciences during the fourth quarter valued at about $203,000. Finally, Mariner LLC boosted its position in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after purchasing an additional 869 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $54.27.

IDEAYA Biosciences Stock Up 1.5%

IDYA opened at $18.08 on Tuesday. The company has a market cap of $1.58 billion, a P/E ratio of -5.48 and a beta of 0.26. The firm's 50-day moving average price is $17.63 and its 200-day moving average price is $22.11. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) EPS. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.